Dupilumab in atopic dermatitis

Dupilumab may have long-term efficacy in patients with atopic dermatitis.

In a study, published in JAMA Dermatology, researchers assessed the effectiveness and discontinuation rates of 1,286 patients with atopic dermatitis treated between October 2017 and December 2022.

The researchers found that dupilumab maintained clinical effectiveness across all age groups involved in the study, reducing eczema severity and itching scores. About 25% of the patients discontinued dupilumab because of adverse events — such as ocular surface disease and musculoskeletal pain — and a lack of treatment effectiveness. However, 3% of the patients who discontinued treatment were able to restart dupilumab with positive responses.

The findings indicated that dupilumab may provide long-term benefits in the management of atopic dermatitis.

Read more: JAMA Dermatology

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.